MedTrace Logo

Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis

NCT00125333 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2008-11-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether this topical NF-kappaB Decoy candidate is safe in persons with atopic dermatitis. Preliminary evidence of efficacy (whether it is working) will also be evaluated.

Conditions

Interventions

DRUG

NF-kappaB Decoy

Sponsors & Collaborators

  • Anesiva, Inc.

    lead INDUSTRY

Principal Investigators

  • Andria Langenberg, MD · Anesiva, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2005-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00125333 on ClinicalTrials.gov